CX3CL1/Fractalkine Chemokine Domain Antibody [K3M15]

Anwendung: Reaktivität:Mouse

Lane 1: Mouse brain

Experimentiergrundlagen

This antibody requires an anti-rat secondary antibody.

Nutzungsinformationen

Verdünnung
WB1:2000

Anwendung
WB, ELISA

Reaktivität
Mouse

Quelle
Rat Monoclonal Antibody

Lagerpuffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Lagerung (ab dem Datum des Erhalts)
-20°C (avoid freeze-thaw cycles), 2 years

Datasheet & SDS

Biologische Beschreibung

Spezifität
CX3CL1/Fractalkine Chemokine Domain Antibody [K3M15] detects endogenous levels of total CX3CL1/Fractalkine Chemokine Domain protein.

Subzelluläre Lokalisierung
Cell membrane, Membrane, Secreted

Uniprot ID
P78423

Klon
K3M15

Synonym
ABCD-3; C3Xkine; chemokine (C-X3-C motif) ligand 1; CX3C membrane-anchored chemokine; CX3CL1; CXC3; CXC3C; FKN; Fractalkine; Neurotactin; neurotactin); NTNsmall inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine; NTTSmall-inducible cytokine D1; SCYD1C-X3-C motif chemokine 1; small inducible cytokine subfamily D (Cys-X3-Cys), member-

Hintergrund
CX3CL1, also known as fractalkine, is the only member of the CX3C chemokine family and is distinguished by three amino acids separating its first two conserved cysteine residues. It is synthesized as a 373-amino acid type I transmembrane protein consisting of four major domains: an N-terminal chemokine domain that mediates chemoattraction, a mucin-like stalk that supports cell adhesion, a transmembrane segment that anchors the protein to the cell surface, and a cytoplasmic domain involved in intracellular signaling. Fractalkine uniquely exhibits both chemotactic and adhesive properties, acting as a membrane-bound adhesion molecule and, upon cleavage by metalloproteinases ADAM10 and ADAM17, functioning as a soluble chemoattractant. Its receptor, CX3CR1, is a G protein-coupled receptor expressed on immune and vascular cells, including monocytes, macrophages, NK cells, T cells, and smooth muscle cells. The binding of CX3CL1 to CX3CR1 activates multiple signaling pathways, including PI3K, MAPK, AKT, Src, and eNOS, which regulate immune cell adhesion, migration, survival, and resistance to apoptosis. The CX3CL1–CX3CR1 axis is involved in key physiological processes such as immune surveillance, angiogenesis, and tissue repair, while also contributing to the pathogenesis of conditions like atherosclerosis, cancer, and neuroinflammation by promoting inflammatory cell recruitment and vascular dysfunction. Genetic variants in CX3CR1 can alter receptor activity and influence individual susceptibility to inflammatory and degenerative diseases.

Hintergrund

CX3CL1, also known as fractalkine, is the only member of the CX3C chemokine family and is distinguished by three amino acids separating its first two conserved cysteine residues. It is synthesized as a 373-amino acid type I transmembrane protein consisting of four major domains: an N-terminal chemokine domain that mediates chemoattraction, a mucin-like stalk that supports cell adhesion, a transmembrane segment that anchors the protein to the cell surface, and a cytoplasmic domain involved in intracellular signaling. Fractalkine uniquely exhibits both chemotactic and adhesive properties, acting as a membrane-bound adhesion molecule and, upon cleavage by metalloproteinases ADAM10 and ADAM17, functioning as a soluble chemoattractant. Its receptor, CX3CR1, is a G protein-coupled receptor expressed on immune and vascular cells, including monocytes, macrophages, NK cells, T cells, and smooth muscle cells. The binding of CX3CL1 to CX3CR1 activates multiple signaling pathways, including PI3K, MAPK, AKT, Src, and eNOS, which regulate immune cell adhesion, migration, survival, and resistance to apoptosis. The CX3CL1–CX3CR1 axis is involved in key physiological processes such as immune surveillance, angiogenesis, and tissue repair, while also contributing to the pathogenesis of conditions like atherosclerosis, cancer, and neuroinflammation by promoting inflammatory cell recruitment and vascular dysfunction. Genetic variants in CX3CR1 can alter receptor activity and influence individual susceptibility to inflammatory and degenerative diseases.

Referenzen
https://pubmed.ncbi.nlm.nih.gov/33391453/ https://pubmed.ncbi.nlm.nih.gov/24556958/

Referenztabelle zur Auswahl der PVDF-Membran-Porengrößen

Proteingröße	PVDF-Transfermembran Porengröße
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Technischer Support

Handhabungshinweise

Tel: +1-832-582-8158 Ext:3

Wenn Sie weitere Fragen haben, hinterlassen Sie bitte eine Nachricht.

Proteingröße	Trenngel-Prozentsatz
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%